Karyopharm Therapeutics Inc Stock Price, News & Analysis

Karyopharm Therapeutics (KPTI) reported Q1 2025 financial results and clinical progress. Total revenue was $30.0M, with U.S. XPOVIO net product revenue of $21.1M, down from $26.0M in Q1 2024 due to a $5.0M increase in product return reserve. The company reaffirmed its 2025 guidance of $140-155M in total revenue. Key clinical developments include: The Phase 3 SENTRY trial in myelofibrosis passed its futility analysis and is ~80% enrolled, with completion expected in June/July 2025. New Phase 2 data showed promising results for selinexor in treating myelofibrosis, with 67% of patients achieving ≥25% spleen volume reduction. The company reported a net loss of $23.5M ($2.77 per share) and had $70.3M in cash as of March 31, 2025. Management is exploring alternatives to extend cash runway beyond early Q4 2025.

Karyopharm Therapeutics (Nasdaq: KPTI), a commercial-stage pharmaceutical company focused on novel cancer therapies, has scheduled its first quarter 2025 financial results announcement for Monday, May 12, 2025. The company will host a conference call and audio webcast at 4:30 p.m. ET to discuss financial results and provide company updates.

Investors can access the conference call via phone at (800) 836-8184 (local) or (646) 357-8785 (international). A live audio webcast with accompanying slides will be available on the company's investor relations website, with an archived version accessible approximately two hours after the event.

Karyopharm Therapeutics (NASDAQ: KPTI), a commercial-stage pharmaceutical company focused on cancer therapies, has granted 983 restricted stock units (RSUs) to two newly-hired employees as inducement awards. The RSUs were granted on April 30, 2025, under the company's 2022 Inducement Stock Incentive Plan, complying with Nasdaq Listing Rule 5635(c)(4).

The RSUs will vest over a three-year period, with 33 1/3% vesting annually on the grant date anniversary, contingent on continued employment. In case of a change in control event, the RSUs will fully vest if the employee is terminated for "good reason" or without "cause" within one year of the event.

Karyopharm Therapeutics (Nasdaq: KPTI), a commercial-stage pharmaceutical company focused on novel cancer therapies, has announced the granting of 1,850 restricted stock units (RSUs) to two newly-hired employees as of March 31, 2025.

The RSU awards, granted under the Company's 2022 Inducement Stock Incentive Plan, will vest over three years, with 33 1/3% vesting on each anniversary of the Grant Date. The grants were made in accordance with Nasdaq Listing Rule 5635(c)(4) as employment inducements. Additionally, the RSUs include an acceleration clause allowing immediate full vesting if employment is terminated for 'good reason' or without 'cause' within one year of a change in control event.

Karyopharm Therapeutics (Nasdaq: KPTI), a commercial-stage pharmaceutical company focused on novel cancer therapies, has announced the granting of 3,316 restricted stock units (RSUs) to five newly-hired employees as of February 28, 2025.

The RSU awards, granted under the Company's 2022 Inducement Stock Incentive Plan, will vest over three years, with 33 1/3% vesting on each anniversary of the Grant Date. The grants were made in accordance with Nasdaq Listing Rule 5635(c)(4) as employment inducements.

The RSUs include an acceleration clause that allows for immediate full vesting if the employee's employment is terminated for 'good reason' or without 'cause' within one year of a change in control event.

Karyopharm Therapeutics (KPTI) has announced a 1-for-15 reverse stock split effective February 25, 2025, at 5:00 p.m. Eastern Time. The split aims to increase the per-share market price to regain compliance with Nasdaq's minimum bid price requirement.

The stock will begin trading on a split-adjusted basis on February 26, 2025. The reverse split will reduce outstanding shares from approximately 126.2 million to 8.4 million, and authorized shares from 800 million to 53.3 million. Proportionate adjustments will be made to equity incentive plans, outstanding equity awards, warrants, and convertible notes.

No fractional shares will be issued; stockholders will receive cash payments instead. Computershare Trust Company is acting as the exchange agent, and stockholders holding shares electronically need not take action to receive post-split shares.

Karyopharm Therapeutics reported financial results for Q4 and full year 2024, achieving total revenue of $145.2 million and U.S. XPOVIO net product revenue of $112.8 million for the full year. The company provided 2025 guidance with total revenue expected between $140-155 million.

Key updates include modifications to the Phase 3 XPORT-EC-042 trial in endometrial cancer, with enrollment now focusing on patients with pMMR tumors or dMMR tumors ineligible for checkpoint inhibitors. The sample size has been increased to 276 patients, with top-line data expected in mid-2026.

The Phase 3 SENTRY trial in myelofibrosis is on track for enrollment completion in 1H 2025, with top-line data expected in 2H 2025. The company's cash position was $109.1 million as of December 31, 2024, expected to fund operations into Q1 2026.

Karyopharm Therapeutics (Nasdaq: KPTI), a commercial-stage pharmaceutical company focused on novel cancer therapies, has scheduled its fourth quarter and full year 2024 financial results announcement for Wednesday, February 19, 2025. The company will host a conference call and audio webcast at 8:00 a.m. ET on the same day.

Investors can access the conference call via phone at (800) 836-8184 (local) or (646) 357-8785 (international). The webcast and accompanying slides will be available in the Investor section of Karyopharm's website under 'Events & Presentations', with an archived version accessible approximately two hours after the event.

Karyopharm Therapeutics (Nasdaq: KPTI) has announced the granting of 28,000 restricted stock units (RSUs) to three newly-hired employees as of January 31, 2025. These RSU awards were granted under the Company's 2022 Inducement Stock Incentive Plan, in compliance with Nasdaq Listing Rule 5635(c)(4).

The RSUs will vest over three years, with 33 1/3% vesting on each anniversary of the grant date, contingent upon continued employment. In case of a change in control event, the RSUs will fully vest if the employee's employment is terminated for good reason or without cause within one year of such event.